Global Anti-Nuclear Antibody Test Market, By Product (Reagents And Assay Kits, Systems, Software, And Services), Disease (Rheumatoid Arthritis, Systemic Lupus Erythematosus, Sjögren's Syndrome, Scleroderma, And Other Diseases), Technique (Enzyme-Linked Immunoassay, Immunofluorescence Assay, And Multiplex Assay), End Users (Hospitals, Clinical Laboratories, Physician Office Laboratories, And Others End Users) – Industry Trends and Forecast to 2030.
Anti-Nuclear Antibody Test Market Analysis and Size
According to the American Autoimmune Related Disease Association (AARDA), about 50 million people suffer from autoimmune diseases in the U.S., and the incidence is growing yearly. In this regard, these antibody tests are widely used for diagnosis. Furthermore, the growing number of reagent rental agreements and increasing population and healthcare expenditure is also increasing the growth. Several latest research studies show that the immunofluorescence technique in the anti-nuclear antibody assay helps to diagnose diseases more accurately and thus, in a way, helps in market growth.
Data Bridge Market Research analyses the anti-nuclear antibody test market growth rate in the forecast period 2023-2030. The expected CAGR of anti-nuclear antibody test market tends to be around 13% in the mentioned forecast period. The market was valued at USD 1,700.75 million in 2022 and would grow to USD 4,521.35 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Anti-Nuclear Antibody Test Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product (Reagents And Assay Kits, Systems, Software, And Services), Disease (Rheumatoid Arthritis, Systemic Lupus Erythematosus, Sjögren's Syndrome, Scleroderma, And Other Diseases), Technique (Enzyme-Linked Immunoassay, Immunofluorescence Assay, And Multiplex Assay), End Users (Hospitals, Clinical Laboratories, Physician Office Laboratories, And Others End Users)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Erba Mannheim (Germany), Abbott (U.S.), Trinity Biotech (Ireland), Bio-Rad Laboratories, Inc. (U.S.). Thermo Fisher Scientific (U.S.), ZEUS Scientific, Inc. (U.S.), Grifols, S.A (Spain). BioVision Inc (U.S.)., PerkinElmer, Inc. (U.S.)., F. Hoffmann-La Roche Ltd (Switzerland), EUROIMMUN Medizinische Labordiagnostika AG (Germany), Zimmer Biomet, (U.S.)., Smith + Nephew (U.K.), Boston Scientific Corporation (U.S.), Organogenesis Inc. (U.S.) and Arthrex, Inc (Germany)
|
|
Market Opportunities
|
|
Market Definition
Anti-nuclear antibodies are the type of autoantibodies that bind to the cell's unique nucleus contents. Anti-nuclear antibody (ANA) means the fluorescent anti-nuclear antibody (FANA) and anti-nuclear antibody screen. The antibody test helps to detect autoantibodies present in the human blood serum, and in this regard, indirect immunofluorescence and enzyme-linked immunosorbent assay tests are the most widely used tests that are performed.
Anti-Nuclear Antibody Test Market Dynamics
Drivers
- Increasing Product Launches Associated with Disease Diagnostics
Several new diagnostic products for autoimmune diseases will boost the market growth during the study period. For instance, EUROIMMUN, a PerkinElmer, Inc. company, launched the EUROPattern Microscope Live (EPML) compact immunofluorescence microscope in 2021, enabling ultrafast automated immunofluorescence image acquisition. Also, indirect immunofluorescence tests (IIFT) are widely used to detect different antibodies in a patient sample. Thus, this factor will boost market growth.
- Growing Investments by Major Market Players For Antibody Tests
Increasing investments to develop a diagnostic platform for autoimmune diseases such as rheumatoid arthritis and others are anticipated to boost market growth. For instance, Prantae Solutions is being funded under the India-Russia Joint Technology Assessment and Accelerated Commercialization Program in 2021 to develop a platform for rapid point-of-care diagnosis of Rheumatoid Arthritis (RA) by a technique known as multiplex immunofluorescence analysis based on disposable cartridges. Thus, this factor boosts market growth.
Opportunities
- Growing R&D Activities For Anti-nuclear Antibody Assay
Several new research studies using immunofluorescence in the anti-nuclear antibody assay help to diagnose different diseases more effectively, and it is anticipated to have a huge influence on the market. For instance, according to the study published by Arthritis Research & Therapy in 2022, systemic lupus erythematosus (SLE) patients' saliva was assayed for ANA using immunofluorescence (IF). It showed that salivary ANA IF intensities were considerably higher in these patients compared to healthy controls. Thus, growing R&D activities specifying the benefits of immunofluorescence tests will increase global demand, thus boosting the market growth.
- Increasing Demand for Reagents and Assay Kits For Assay
The rising demand for reagents and assay kits boost the total performance of an assay, thus boosting the market's growth. They help create standardized workflows to help researchers in numerous fields. There are standard reagents that help achieve exact and efficient results. Improved efficiency, standardized results, and cost-effectiveness are anticipated to enhance market growth further.
Restraints/Challenges
- Higher Diagnostic Errors Associated With Antibody Tests
An increasing rate of diagnostic errors may hamper the market growth. For instance, according to the American College of Rheumatology, healthy people with no health conditions or using medicines such as isoniazid and procainamide show false positive anti-nuclear antibody tests. This test lacks a great amount of specificity. Thus, this factor hampers the market growth.
This anti-nuclear antibody test market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the anti-nuclear antibody test market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In 2022, THERADIAG made an agreement with Quotient Limited, a commercial-stage diagnostics company. The two companies will enter into partnership to boost autoimmune diagnostics by leveraging Quotient's MosaiQ platform.
- In 2022, ZEUS Scientific received FDA clearance for the ZEUS dIFine IFA system for use with ZEUS' ANA HEp-2 indirect fluorescent antibody (IFA) assay. FDA clearance of HEp-2 ANA IFA test system on the dIFine system includes positive and negative determination and eight common ANA HEp-2 staining patterns.
Global Anti-Nuclear Antibody Test Market Scope
The anti-nuclear antibody test market is segmented on the basis of product, disease, technique and end users. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product
- Reagents And Assay Kits
- Systems
- Software And Services
Disease
- Rheumatoid Arthritis
- Systemic Lupus Erythematosus
- Sjögren's Syndrome
- Scleroderma
- Other Diseases
Technique
- Enzyme-Linked Immunoassay
- Immunofluorescence Assay
- Multiplex Assay
End-user
- Hospitals
- Clinical Laboratories
- Physician Office Laboratories
- Others End Users
Anti-Nuclear Antibody Test Market Regional Analysis/Insights
The anti-nuclear antibody test market is analyzed and market size insights and trends are provided by product, disease, technique and end users as referenced above.
The major countries covered in the anti-nuclear antibody test market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific has been witnessing positive growth for the anti-nuclear antibody test market throughout the forecast period due to various unmet clinical needs and needs for better diagnosis. Unmet needs for autoimmune disease diagnostics in several countries, such as India, are anticipated to boost the regional demand during the forecast period.
North America dominates the market due to the most well-established markets concerning the adoption of ANA testing, healthcare infrastructure, patient awareness, and the increasing presence of advanced tests. Thus, these factors enhance the growth of the market.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Anti-Nuclear Antibody Test Market Share Analysis
The anti-nuclear antibody test market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related anti-nuclear antibody test market.
Key players operating in the anti-nuclear antibody test market include:
- Erba Mannheim (Germany)
- Abbott (U.S.)
- Trinity Biotech (Ireland)
- Bio-Rad Laboratories, Inc. (U.S.)
- Thermo Fisher Scientific (U.S.)
- ZEUS Scientific, Inc. (U.S.),
- Grifols, S.A (Spain)
- BioVision Inc (U.S.)
- PerkinElmer, Inc. (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- EUROIMMUN Medizinische Labordiagnostika AG (Germany)
- Zimmer Biomet, (U.S.)
- Smith + Nephew (U.K.)
- Boston Scientific Corporation (U.S.)
- Organogenesis Inc. (U.S.)
- Arthrex, Inc (Germany)
SKU-